Vaxart’s Stock Slumps 64%: Why Investors Are Watching the Oral Flu Vaccine Company Closely
Vaxart’s stock dives 64%, negative P/E, and weak earnings flag deep financial risk for the oral flu‑vaccine biotech, urging investors to watch its struggle for profitability.
2 minutes to read






